Lissun has raised ₹48 crore in a highly awaited Series A funding round. The platform is notably centered on providing specialized assistance and sophisticated treatments to children with special needs and developmental delays.

Colossa Ventures led this investment round. The key funding infusion is a sign of investor optimism in healthcare providers that play in very niche and important areas of the healthcare sector, especially the critical childhood behavioral and developmental health space.

Fund utilization and operational growth

With a valuation of ₹48 crore, this Series A round attracted considerable support from a wide range of esteemed venture capital firms and investment networks. Colossa Ventures spearheaded this financial initiative with robust backing from Physis Capital, other existing investors, and those who reaffirmed their trust in the company’s vision. 

Current investors include RPSG Capital Ventures, Ivycap Ventures, Rainmatter, Multiply Ventures, and SucSEED Ventures. The company successfully secured new funds from new investors, including the New Age India Fund and Beyond Capital Ventures. 

This latest success further consolidates the company’s financial standing, following a $2.5 million pre-Series A round earlier in September, 2024, led by RPSG Capital Ventures. In June this year, the platform raised ₹2.77 crore from Zerodha and other investors.

The newly acquired ₹48 crore has facilitated Lissun to develop a strategic and comprehensive blueprint for the allocation of funds to speed up its overall mission. A significant part of this new fund will be used to strongly fund the development of the company’s specialized centers, according to the company’s statement published in the press release. 

The company envisions the spread of its specialized children’s care arm, named Sunshine by LISSUN, to several prime cities around the nation. The health-tech platform is not just expanding its physical footprint, but it is also committed to directing resources toward its next generation of highly sophisticated, AI-powered solutions. 

The startup’s proprietary technology and built-up data can be harnessed to transform care delivery. The capital will contribute to the improvement and consolidation of the clinical processes used throughout its entire operational system.

Lissun was established in 2021 by Krishna Veer Singh and Tarun Gupta, who are entrepreneurs, and it functions primarily under its flagship entity Sunshine by LISSUN, a child-care brand. With this brand, the company streamlines its network of child development centers across India with a set of digital products and foresightfully harnesses innovative AI-powered tools. 

The startup’s operational development over the last 1 year has been truly remarkable, and the official press release reports the company’s total growth by 4 times. The platform currently performs over 10,000 essential therapy sessions every month. The high demand for their niche healthcare services is reflected by the large scale of their therapeutic interventions delivered through a dense network of 25 physical clinics.

Strategic expansion plans and competitive landscape

Lissun has ambitious plans for expanding its lines. The platform has ambitious digital outreach targets, expecting that its digital products will bring and help 10 lakh-plus children in this country in the next few years. The expansion of this massive size is rooted deeply in studies about the critical healthcare system in India. 

The demand for developmental and behavioral care with special focus on children is currently expanding at a fast pace throughout the nation. Access to high-quality, consistent care continues to be alarmingly low and severely disjointed. 

Lissun is actively addressing this vast disparity with Sunshine by LISSUN, a refined platform where the cutting-edge capabilities of human expertise and sophisticated AI are seamlessly combined, easily accessible at physical locations and via digital modality.

The health-tech space is seeing the rise of several niche startups; the single-specialty category in which the focus is being keenly laid on the designing of products dedicated to children with special needs and developmental delays. 

The spectrum of activities of these companies spans several critical areas, including early screening, diagnosis support, comprehensive therapy, detailed developmental care for complex disorders like autism and ADHD, along with speech and language disorders. 

In this competitive area, Lissun is able to rival some of the prominent sites such as Butterfly Learnings, Continua Kids, Hoola Health, and Children First from Amaha. The industry has seen substantial financial transactions over the last few years, reflecting its vast potential. 

Lissun’s role in addressing the lack and isolation of developmental and behavioral care for children with a diagnosis such as autism and ADHD is making a truly meaningful difference in the special sphere of developmental and behavioral care. With the establishment of 50 physical locations and the goal of reaching over 10 lakh children online, this investment will likely play a crucial role in advancing the startup’s mission to provide consistent, high-quality, and accessible care to the children most in need in a fast-evolving and competitive market environment.

Conclusion

The significant Series A funding opportunity of ₹48 crore that Lissun has secured is marking a pivotal moment for this platform and the entire pediatric healthcare tech sector in India. The company is well-positioned to aggressively expand the Sunshine by LISSUN centers, its proprietary AI algorithm and technological tools, with the support of Colossa Ventures and an influential group of new and existing investors.